J
José Garnacho-Montero
Researcher at Spanish National Research Council
Publications - 197
Citations - 12603
José Garnacho-Montero is an academic researcher from Spanish National Research Council. The author has contributed to research in topics: Intensive care & Intensive care unit. The author has an hindex of 54, co-authored 175 publications receiving 10780 citations. Previous affiliations of José Garnacho-Montero include University of Barcelona & University of Seville.
Papers
More filters
Journal ArticleDOI
Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain.
Ricard Ferrer,Antonio Artigas,Mitchell M. Levy,Jesús Blanco,Gumersindo González-Díaz,José Garnacho-Montero,Jordi Ibáñez,Eduardo Palencia,Manuel Quintana,María Victoria de la Torre-Prados +9 more
TL;DR: A national educational effort to promote bundles of care for severe sepsis and septic shock was associated with improved guideline compliance and lower hospital mortality.
Journal ArticleDOI
Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis.
José Garnacho-Montero,Jose Luis García-Garmendía,A Barrero-Almodóvar,Francisco J. Jimenez-Jimenez,C. Pérez-Paredes,Carlos Ortiz-Leyba +5 more
TL;DR: In patients admitted to the ICU for sepsis, the adequacy of initial empirical antimicrobial treatment is crucial in terms of outcome, although early mortality rate was unaffected by the appropriateness of empirical antibiotic therapy.
Journal ArticleDOI
A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization*
Cristóbal León,Sergio Ruiz-Santana,Pedro Saavedra,Benito Almirante,Juan Nolla-Salas,Francisco Álvarez-Lerma,José Garnacho-Montero,MA León +7 more
TL;DR: In a large cohort of nonneutropenic critically ill patients in whom Candida colonization was prospectively assessed, a “Candida score” >2.5 accurately selected patients who would benefit from early antifungal treatment.
Journal ArticleDOI
Treatment of Multidrug-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia (VAP) with Intravenous Colistin: A Comparison with Imipenem-Susceptible VAP
José Garnacho-Montero,C. Ortiz-Leyba,F. J. Jiménez-Jiménez,A Barrero-Almodóvar,J. L. García-Garmendia,M. Bernabeu-Wittell,S. L. Gallego-Lara,J. Madrazo-Osuna +7 more
TL;DR: Intravenous colistin appears to be a safe and effective alternative to imipenem for the management of VAP due to carbapenem-resistant strains of A. baumannii.
Journal ArticleDOI
Critical illness polyneuropathy: risk factors and clinical consequences. A cohort study in septic patients.
José Garnacho-Montero,J. Madrazo-Osuna,J. L. García-Garmendia,C. Ortiz-Leyba,F. J. Jiménez-Jiménez,A Barrero-Almodóvar,M.C Garnacho-Montero,M R Moyano-Del-Estad +7 more
TL;DR: Hyperosmolality, parenteral nutrition, non-depolarizing neuromuscular blockers and neurologic failure can favor CIP development, and CIP is associated with increased duration of mechanical ventilation and in-hospital mortality.